Document Type

Article

Original Publication Date

2015

Journal/Book/Conference Title

Expert Reviews of Proteomics

Volume

12

Issue

1

First Page

75

Last Page

82

DOI of Original Publication

doi:10.1586/14789450.2015.1000869

Comments

Author manuscript (available in PMC 2015 November 30) of an article published in final edited form as: Expert Rev Proteomics. 2015 February ; 12(1): 75–82. doi:10.1586/14789450.2015.1000869.

This work was supported in part by the National Institutes of Health grant NS055012 and Virginia Commonwealth School of Medicine. The authors have no relevant affiliations or financial involvement with any organization or entity with a financial interest in or financial conflict with the subject matter or materials discussed in the manuscript. This includes employment, consultancies, honoraria, stock ownership or options, expert testimony, grants or patents received or pending, or royalties.

Date of Submission

February 2018

Abstract

Effective traumatic brain injury (TBI) therapeutics remain stubbornly elusive. Efforts in the field have been challenged by the heterogeneity of clinical TBI, with greater complexity among underlying molecular phenotypes than initially conceived. Future research must confront the multitude of factors comprising this heterogeneity, representing a big data challenge befitting the coming informatics age. Proteomics is poised to serve a central role in prescriptive therapeutic development, as it offers an efficient endpoint within which to assess post-TBI biochemistry. We examine rationale for multifactor TBI proteomic studies and the particular importance of temporal profiling in defining biochemical sequences and guiding therapeutic development. Lastly, we offer perspective on repurposing biofluid proteomics to develop theragnostic assays with which to prescribe, monitor and assess pharmaceutics for improved translation and outcome for TBI patients.

Is Part Of

VCU Anatomy and Neurobiology Publications

Share

COinS